- Everything You Need to Know About Breast Density, From the Experts
- First Doses of Mpox Vaccine Reach Africa, But Many More Are Needed
- Seeing Through: Scientists Use Food Dye to Render Mouse Skin Transparent
- Gun Deaths to Children and Teens Have Risen in Almost All States
- Too Much Light at Night Linked to Higher Alzheimer’s Risk
- Almost 1 in 4 U.S. Adults Under 40 Have High Blood Pressure
- Exposure to PFAS ‘Forever Chemicals’ in Pregnancy Could Boost Long-Term Obesity Risk
- Cuffs on At-Home Blood Pressure Monitors Don’t Fit Some Patients
- Brain’s Wiring May Trigger Depression in Some People
- Saltwater Drops in Nose Could Shorten Kids’ Colds
Eye Tests Might Help ID Alzheimer’s, Studies Suggest
![](https://ladylively.com/wp-content/uploads/2013/08/health-tech6-300x336.jpg)
Eye tests could be used to identify people in the early stages of Alzheimer’s disease, two new studies suggest.
In one study, early results from 40 participants who used a certain eye test found a significant association between levels of beta-amyloid plaques in the retina of the eye and levels of the plaques in the brain. Beta-amyloid plaques in the brain are associated with Alzheimer’s disease.
This type of eye test could be used in conjunction with the brain scans and clinical tests currently relied on to diagnose Alzheimer’s, study author Shaun Frost, of the Commonwealth Scientific and Industrial Research Organization in Australia, said in a news release from the Alzheimer’s Association.
The eye test could also be used to monitor the progression of Alzheimer’s and a patient’s response to treatment, Frost added.
The preliminary results were scheduled for release at the annual meeting of the Alzheimer’s Association in Copenhagen, Denmark, which started Sunday. The full study, involving 200 participants, is expected to be completed later this year.
Another study presented at the meeting utilized a different type of eye test. It found a strong link between levels of beta-amyloid plaques in the lens of the eye and in the brain.
“There is a critical need for a fast, dependable, low-cost and readily available test for the early diagnosis and management of Alzheimer’s disease,” Dr. Pierre Tariot, director of the Banner Alzheimer’s Institute in Phoenix, Ariz., said in an Alzheimer’s Association news release. Tariot was a principal investigator in the study.
Research presented at meetings is considered preliminary until published in a peer-reviewed medical journal.
More information
The U.S. National Library of Medicine has more about Alzheimer’s disease.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.